1,403 results on '"Bradner, James E."'
Search Results
2. Author Correction: Diversity-oriented synthesis encoded by deoxyoligonucleotides
3. Diversity-oriented synthesis encoded by deoxyoligonucleotides
4. Genome-scale functional genomics identify genes preferentially essential for multiple myeloma cells compared to other neoplasias
5. Selective targeting of MYC mRNA by stabilized antisense oligonucleotides
6. The synergy of BET inhibitors with aurora A kinase inhibitors in MYCN-amplified neuroblastoma is heightened with functional TP53.
7. Discovery and characterization of a selective IKZF2 glue degrader for cancer immunotherapy
8. BET-bromodomain and EZH2 inhibitor–treated chronic GVHD mice have blunted germinal centers with distinct transcriptomes
9. Targetable BET proteins- and E2F1-dependent transcriptional program maintains the malignancy of glioblastoma
10. Combined BET bromodomain and CDK2 inhibition in MYC-driven medulloblastoma
11. CRISPR-Cas9 screen reveals a MYCN-amplified neuroblastoma dependency on EZH2
12. An IMiD-inducible degron provides reversible regulation for chimeric antigen receptor expression and activity
13. BET bromodomain inhibition suppresses innate inflammatory and profibrotic transcriptional networks in heart failure.
14. Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma
15. Synergistic effect of JQ1 and rapamycin for treatment of human osteosarcoma.
16. The BET inhibitor JQ1 attenuates double-strand break repair and sensitizes models of pancreatic ductal adenocarcinoma to PARP inhibitors
17. Epigenetic targeting of Hedgehog pathway transcriptional output through BET bromodomain inhibition.
18. MLL3 Is a Haploinsufficient 7q Tumor Suppressor in Acute Myeloid Leukemia
19. BET Bromodomain Inhibition of MYC-Amplified Medulloblastoma
20. Gastrointestinal stromal tumor enhancers support a transcription factor network predictive of clinical outcome
21. BET bromodomain proteins regulate enhancer function during adipogenesis
22. Synthetic transcription elongation factors license transcription across repressive chromatin
23. Diminished microRNA-29b level is associated with BRD4-mediated activation of oncogenes in cutaneous T-cell lymphoma
24. A Chemoproteomic Approach to Query the Degradable Kinome Using a Multi-kinase Degrader
25. Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition
26. BET bromodomain-targeting compounds reactivate HIV from latency via a Tat-independent mechanism
27. MTHFD1 interaction with BRD4 links folate metabolism to transcriptional regulation
28. Small-molecule targeting of brachyury transcription factor addiction in chordoma
29. A non-canonical SWI/SNF complex is a synthetic lethal target in cancers driven by BAF complex perturbation
30. Small-Molecule Inhibition of Proteasome and Aggresome Function Induces Synergistic Antitumor Activity in Multiple Myeloma
31. Data from Targeting STAT5 in Hematologic Malignancies through Inhibition of the Bromodomain and Extra-Terminal (BET) Bromodomain Protein BRD2
32. Data from BET Bromodomain Inhibition Cooperates with PD-1 Blockade to Facilitate Antitumor Response in Kras-Mutant Non–Small Cell Lung Cancer
33. Figure S2 from JQ1 Induces DNA Damage and Apoptosis, and Inhibits Tumor Growth in a Patient-Derived Xenograft Model of Cholangiocarcinoma
34. Data from BET Protein Antagonist JQ1 Is Synergistically Lethal with FLT3 Tyrosine Kinase Inhibitor (TKI) and Overcomes Resistance to FLT3-TKI in AML Cells Expressing FLT-ITD
35. Supplementary Figure 1 from RapidCaP, a Novel GEM Model for Metastatic Prostate Cancer Analysis and Therapy, Reveals Myc as a Driver of Pten-Mutant Metastasis
36. Supplementary Figure 2 from Chronic Myelogenous Leukemia– Initiating Cells Require Polycomb Group Protein EZH2
37. Data from Harnessing Connectivity in a Large-Scale Small-Molecule Sensitivity Dataset
38. Supplementary Figure 3 from RapidCaP, a Novel GEM Model for Metastatic Prostate Cancer Analysis and Therapy, Reveals Myc as a Driver of Pten-Mutant Metastasis
39. Suppllementary Methods and Supplementary Figures 1-5 from BET Inhibition Induces Apoptosis in Aggressive B-Cell Lymphoma via Epigenetic Regulation of BCL-2 Family Members
40. Supplementary Table 2 from Chronic Myelogenous Leukemia– Initiating Cells Require Polycomb Group Protein EZH2
41. Data from Oncogenic Deregulation of EZH2 as an Opportunity for Targeted Therapy in Lung Cancer
42. Supplementary Figure 5 from Chronic Myelogenous Leukemia– Initiating Cells Require Polycomb Group Protein EZH2
43. Data from JQ1 Induces DNA Damage and Apoptosis, and Inhibits Tumor Growth in a Patient-Derived Xenograft Model of Cholangiocarcinoma
44. Data from BET Inhibition Induces Apoptosis in Aggressive B-Cell Lymphoma via Epigenetic Regulation of BCL-2 Family Members
45. Data from Targeting Chromatin Regulators Inhibits Leukemogenic Gene Expression in NPM1 Mutant Leukemia
46. Supplementary Figure 1 from Chronic Myelogenous Leukemia– Initiating Cells Require Polycomb Group Protein EZH2
47. Supplementary Figure 3 from Chronic Myelogenous Leukemia– Initiating Cells Require Polycomb Group Protein EZH2
48. Supplementary Figure Legends from BET Bromodomain Inhibition Cooperates with PD-1 Blockade to Facilitate Antitumor Response in Kras-Mutant Non–Small Cell Lung Cancer
49. Supplementary Table Legend from Mechanism, Consequences, and Therapeutic Targeting of Abnormal IL15 Signaling in Cutaneous T-cell Lymphoma
50. Table S1-S3; Figure S1-S13 from BET Bromodomain Inhibition Cooperates with PD-1 Blockade to Facilitate Antitumor Response in Kras-Mutant Non–Small Cell Lung Cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.